Wenckebach Block (Mobitz Type I AV Block)

Overview

Wenckebach block, also called Mobitz type I second‑degree atrioventricular (AV) block, is a rhythm disturbance in which electrical impulses from the atria to the ventricles become progressively delayed until one impulse is completely blocked. The pattern repeats in a predictable cycle, producing a characteristic “progressive PR‑interval lengthening” on an electrocardiogram (ECG).

Who it affects

• Most commonly seen in adults over 50 years old.
• Often discovered incidentally during routine exams or pre‑operative testing.
• Can occur in children with congenital heart disease or after cardiac surgery, but this is less common.

Prevalence

• Second‑degree AV block accounts for roughly 0.02–0.04% of the general population, with Mobitz I comprising about 30–40% of those cases (Mayo Clinic, 2023).
• Incidence rises to 1–2% in patients with structural heart disease or after cardiac valve surgery.

Symptoms

Many people with Wenckebach block have no symptoms at all. When symptoms occur, they are usually related to intermittent pauses in ventricular contraction.

• Palpitations – a feeling of skipped beats or “fluttering” in the chest.
• Dizziness or light‑headedness – especially when standing quickly (orthostatic change).
• Syncope (fainting) – rare in isolated Mobitz I but may happen if pauses exceed 3–4 seconds.
• Fatigue or reduced exercise tolerance – the heart’s output may be insufficient during activity.
• Chest discomfort – can arise from reduced coronary perfusion during pauses.
• Shortness of breath – especially on exertion, reflecting temporary low cardiac output.
• Altered awareness – trouble concentrating, “brain fog” during prolonged pauses.

When symptoms are absent, the condition is usually classified as “asymptomatic” and may require only observation.

Causes and Risk Factors

Primary causes

• Intrinsic conduction system disease – age‑related fibrosis or sclerosis of the AV node.
• Vagal tone – heightened parasympathetic activity (e.g., during sleep, in athletes, or after meals) can accentuate the PR‑interval prolongation.
• Medication‑induced – beta‑blockers, calcium‑channel blockers (verapamil, diltiazem), digoxin, and certain antiarrhythmics slow AV nodal conduction.
• Ischemia – coronary artery disease affecting the AV node’s blood supply.
• Inflammation or infiltrative disease – Lyme disease, sarcoidosis, amyloidosis.

Risk factors

• Age > 50 years.
• History of myocardial infarction or chronic heart failure.
• Cardiac surgery, especially valve replacement or repair.
• Use of AV‑node‑blocking drugs.
• High vagal tone (e.g., endurance athletes, sleep apnea).
• Autoimmune or infectious conditions that can involve the conduction system.

Diagnosis

Diagnosis relies on a combination of clinical evaluation and specific cardiac tests.

Electrocardiogram (ECG)

• Typical finding: progressive lengthening of the PR interval over successive beats until a P‑wave is not followed by a QRS complex (a “dropped” beat). The cycle then resets.
• Ratio of conducted beats to dropped beats is usually 3:1 or 4:1, but can vary.

Holter monitor (24‑48 hour ambulatory ECG)

• Captures intermittent episodes and determines the longest pause.
• Useful when symptoms are sporadic.

Exercise stress testing

• Assesses whether the block worsens with increased heart rate; Mobitz I often improves with exercise because sympathetic tone shortens the PR interval.

Event recorder / Loop recorder

• Implanted devices for patients with infrequent symptoms; record rhythm for months to years.

Blood tests

• Thyroid function, electrolyte panel, and drug levels (e.g., digoxin) help identify reversible causes.

Imaging

• Echocardiogram to evaluate structural heart disease.
• Cardiac MRI or CT if infiltrative disease is suspected.

Treatment Options

Management is individualized based on symptom burden, underlying cause, and the length of pauses observed.

Observation

• Asymptomatic patients with brief pauses (<3 seconds) often require only regular follow‑up.
• Annual ECG or periodic Holter monitoring is typical.

Medication review

• Discontinue or reduce doses of AV‑node‑blocking drugs when possible.
• Switch to alternative agents if rate control is needed (e.g., use of an atrial‑specific anti‑arrhythmic).

Pharmacologic therapy

• No specific drugs treat the block itself; however, atropine can be used acutely if a patient becomes symptomatic during monitoring.
• Isoproterenol infusion may be employed temporarily in a monitored setting.

Permanent Pacemaker

• Indicated when:
  • Symptomatic pauses ≥3 seconds or syncope attributable to the block.
  • Progression to higher‑grade AV block (Mobitz II or complete heart block).
  • Underlying structural heart disease with high risk of progression.
• Single‑chamber (VVI) pacing is often sufficient, but dual‑chamber (DDDR) may be chosen for patients with sinus node dysfunction or atrial arrhythmias.
• Modern devices are MRI‑compatible and have longevity of 8–10 years.

Lifestyle modifications

• Maintain adequate hydration to avoid vagally mediated slowing.
• Avoid abrupt position changes; rise slowly from sitting or supine.
• Limit alcohol intake, which can potentiate AV‑node‑blocking effects.

Living with Wenckebach Block (Mobitz Type I AV Block)

• Regular follow‑up – schedule cardiology visits every 6–12 months or as directed.
• Self‑monitoring – keep a log of any palpitations, dizziness, or fainting episodes and note activity at the time.
• Medication adherence – take prescribed drugs exactly as ordered; inform your physician of over‑the‑counter or herbal supplements.
• Physical activity – most patients can engage in moderate exercise; start slowly and avoid extreme endurance training until cleared.
• Travel considerations – carry a copy of your ECG and a list of medications; plan for access to medical care in case of syncope.
• Emergency identification – consider wearing a medical alert bracelet indicating “Mobitz I AV block” and any implanted device.

Prevention

While intrinsic conduction disease cannot be wholly prevented, risk can be mitigated:

• Control cardiovascular risk factors: blood pressure, cholesterol, diabetes, and smoking cessation.
• Prompt treatment of infections that can affect the conduction system (e.g., Lyme disease).
• Regular review of medications that depress AV nodal conduction.
• Manage sleep apnea, which can increase vagal tone during nocturnal periods.

Complications

• Progression to higher‑grade AV block – up to 5% of patients may develop Mobitz II or complete heart block over several years (Cleveland Clinic, 2022).
• Syncope and injury – due to transient cerebral hypoperfusion during prolonged pauses.
• Heart failure exacerbation – if bradycardia leads to reduced cardiac output.
• Sudden cardiac death – rare in isolated Wenckebach, but risk rises if block coexists with ventricular arrhythmias.

When to Seek Emergency Care

References

• Mayo Clinic. “Second‑degree AV block (Mobitz I & II).” Updated 2023.
• American Heart Association. “Guidelines for the Management of Patients with Bradyarrhythmias.” 2022.
• Cleveland Clinic. “AV Block: Diagnosis and Treatment.” 2022.
• National Institutes of Health. “Cardiac Conduction System Disorders.” 2023.
• World Health Organization. “Global Burden of Cardiovascular Diseases.” 2021.